As the S&P 500 tumbled 15% over the past two months, shares of biotech Gilead Sciences (GILD) went in a somewhat different direction: Up 15%.And now it looks like Gilead is going up some more.New data from a University of Chicago Hospital Phase 3 clinical trial of Gilead’s remdesivir antiviral drug, also known as “GS-5734” shows promising results for the drug’s efficacy in treating the novel coronavirus. And no sooner had the data come out, than Gilead’s stock price began marching higher again, rising 12% in pre-market trading on Friday.So what did the data show, exactly?The study in question involved …read more
Source:: Yahoo Finance
